News Releases

May 2019

May 15, 2019 5/15/2019 Takeda to host two panel discussions at American Psychiatric Association Meeting

May 9, 2019 5/9/2019 U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®)

April 2019

April 30, 2019 4/30/2019 Takeda Opens New Global Research Center in San Diego

April 2, 2019 4/2/2019 Motegrity™ (prucalopride), the Only Serotonin-4 Receptor Agonist for Adults with Chronic Idiopathic Constipation (CIC), is Now Available in the United States

March 2019

March 18, 2019 3/18/2019 Takeda receives U.S. FDA Approval to Manufacture FLEXBUMIN

January 2019

January 11, 2019 1/11/2019 Takeda Announces Outcome of Uloric FDA Advisory Committee Meeting

October 2018

October 26, 2018 10/26/2018 New Study Used Personalized Goals to Assess Treatment Effectiveness for Patients with Major Depressive Disorder

October 22, 2018 10/22/2018 New Data Added to TRINTELLIX® (vortioxetine) Labeling